EU HTA

In January 2026, the HTA Coordination Group published the report on Emerging Health Technologies identified in 2025 within the framework of the EU Regulation on Health Technology Assessment (HTAR). The report provides information on technologies (including 15 medical devices) that may be eligible for Joint Clinical Assessments (JCAs) at the EU level from 2026.

On January 07, 2026, the submission period for Joint Scientific Consultations (JSCs) requests under the EU Health Technology Assessment Regulation (HTAR) framework opened. JSCs offer health technology developers the opportunity to seek scientific advice on the information and evidence required for a potential future Joint Clinical Assessment. Requests related to both medical devices and medicines can be submitted until February 04, 2026.

On November 28, 2025, the Member State Coordination Group on Health Technology Assessment (HTACG) published its annual Work Programme for 2026, outlining the priorities and activities within the joint EU-level HTA framework (EU HTAR). In 2026, HTACG plans to initiate about five joint clinical assessments (JCAs) for medical devices with the first assessments expected to start in June 2026. The Work Programme also sets out the 2026 schedule for Joint Scientific Consultations (JSCs).

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its EU HTA Publications Digest. In a recent publication, Severens et al. analyzed Europe-wide perspectives on the implementation of the EU HTA Regulation, mapping key implementation challenges and proposing actions to support a smoother transition.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its EU HTA Publications Digest. In a recent publication, Mezei et al. examined regulatory and methodological barriers affecting digital health technologies, drawing on surveys, interviews, and focus groups with developers from ten European countries.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its EU HTA Publications Digest. In a recent publication, Johns et al. examined the practical implications of the EU Joint Clinical Assessment (JCA) for countries considering cost-effectiveness analyses.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its EU HTA Publications Digest. In a recent publication, Sciattella et al. shared the outcomes of the 2024 Italian Health Policy Forum, which explored how Italy is preparing for the implementation of the EU HTA Regulation 2021/2282.

On October 17, 2025, the European Commission adopted an implementing regulation that sets detailed procedural rules for Joint Clinical Assessments of medical devices and in vitro diagnostics under the HTA Regulation, which entered into force on 12 January 2025.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its EU HTA Publications Digest. In a recent publication, Boers et al. introduced the Common European Classification Grid (CEUGrid-DMD) and an Evidence Matrix to harmonize the evaluation of digital medical devices (DMDs) across the EU.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its EU HTA Publications Digest. In a recent publication, Eberle et al. explored whether the PICO elements (Population, Intervention, Comparator, Outcome) applied in EU Joint Clinical Assessments (JCAs) can be predicted across member states using publicly available data from national HTA bodies.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its EU HTA Publications Digest. In a recent publication, Pickaert analysed patient involvement practices in HTA across seven countries (Canada, England, Scotland, France, Germany, Spain, and Italy) to identify lessons for the EU Joint Clinical Assessment (JCA) framework.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its EU HTA Publications Digest. In a recent publication, Willemsen et al. analyzed the Dutch response to the EU Health Technology Assessment Regulation (HTAR), which took effect in January 2025.